Bellevue Group Ag Ligand Pharmaceuticals Inc Transaction History

Bellevue Group Ag

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 14, 2020	SELL	$63.37 - $107.88 $982,235 - $1.67 Million	-15,500 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$96.94 - $113.59 $1.5 Million - $1.76 Million	15,500 New	15,500 $1.62 Million
Q1 2019 May 15, 2019	SELL	$105.93 - $142.47 $2.53 Million - $3.4 Million	-23,870 Closed	0 $0
Q4 2018 Feb 12, 2019	BUY	$128.36 - $272.13 $1.62 Million - $3.43 Million	12,600 Added 111.8%	23,870 $3.24 Million
Q3 2018 Nov 13, 2018	SELL	$211.18 - $274.49 $168,944 - $219,592	-800 Reduced 6.63%	11,270 $3.09 Million
Q2 2018 Aug 07, 2018	SELL	$150.77 - $207.98 $690,526 - $952,548	-4,580 Reduced 27.51%	12,070 $2.5 Million
Q1 2018 May 09, 2018	SELL	$138.63 - $182.62 $1.21 Million - $1.6 Million	-8,750 Reduced 34.45%	16,650 $2.75 Million
Q4 2017 Feb 14, 2018	SELL	$128.36 - $147.04 $2.99 Million - $3.43 Million	-23,300 Reduced 47.84%	25,400 $3.48 Million
Q3 2017 Nov 13, 2017	SELL	$120.91 - $137.94 $1.78 Million - $2.03 Million	-14,700 Reduced 23.19%	48,700 $6.63 Million
Q2 2017 Aug 14, 2017	BUY	N/A	63,400	63,400 $7.7 Million

279

19M

9.5K

8.1K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.75B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.